Urinary Bladder Neoplasms Clinical Trials

15 recruiting

Urinary Bladder Neoplasms Trials at a Glance

15 actively recruiting trials for urinary bladder neoplasms are listed on ClinicalTrialsFinder across 6 cities in 31 countries. The largest study group is Phase 1 with 4 trials, with the heaviest enrollment activity in Madrid, New York, and London. Lead sponsors running urinary bladder neoplasms studies include Eli Lilly and Company, Merck Sharp & Dohme LLC, and Cancer Research UK.

Browse urinary bladder neoplasms trials by phase

Treatments under study

About Urinary Bladder Neoplasms Clinical Trials

Looking for clinical trials for Urinary Bladder Neoplasms? There are currently 15 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Urinary Bladder Neoplasms trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Urinary Bladder Neoplasms clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 115 of 15 trials

Recruiting
Phase 1Phase 2

A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)

Urinary Bladder NeoplasmsBladder Cancer
Merck Sharp & Dohme LLC45 enrolled14 locationsNCT07222488
Recruiting
Phase 3

Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)

Urinary Bladder NeoplasmsImmune Checkpoint InhibitorsMethotrexate+4 more
AstraZeneca150 enrolled59 locationsNCT06960577
Recruiting
Phase 1

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

Carcinoma, Non-Small Cell LungSquamous Cell Carcinoma of Head and NeckHER2 Negative Breast Neoplasms+9 more
Seagen, a wholly owned subsidiary of Pfizer1,006 enrolled158 locationsNCT04389632
Recruiting
Phase 1

FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3

Urinary Bladder NeoplasmsNeoplasm MetastasisUreteral Neoplasms
Eli Lilly and Company535 enrolled84 locationsNCT05614739
Recruiting
Phase 3

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

Urinary Bladder NeoplasmsNeoplasm MetastasisCarcinoma, Transitional Cell
Eli Lilly and Company450 enrolled281 locationsNCT07218380
Recruiting
Phase 2

A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)

Urinary Bladder NeoplasmsNon-Muscle Invasive Bladder Neoplasms
Merck Sharp & Dohme LLC308 enrolled89 locationsNCT06833073
Recruiting
Not Applicable

Early vs Delayed Intravesical Blad-Care During BCG Therapy

Urinary Bladder NeoplasmsBCG-Induced Cystitis
BLAD-HYA Group56 enrolled1 locationNCT07495072
Recruiting

Lymphedema After Urologic Surgery

Urinary Bladder NeoplasmsPenile CancerProstatic Neoplasms+1 more
Vastra Gotaland Region400 enrolled2 locationsNCT05264337
Recruiting
Early Phase 1

Virtual Histology of the Bladder Wall for Bladder Cancer Staging

Urinary Bladder Neoplasms
Jodi Maranchie42 enrolled1 locationNCT04369560
Recruiting
Not Applicable

FAPI and FDG PET/MRI in Diagnosis and Therapy Prediction of Bladder Cancer

Urinary Bladder Neoplasms
First Affiliated Hospital of Fujian Medical University80 enrolled1 locationNCT06421142
Recruiting
Phase 1Phase 2

HTL0039732 in Participants With Advanced Solid Tumours

SarcomaUrinary Bladder NeoplasmsUterine Cervical Neoplasms+11 more
Cancer Research UK150 enrolled5 locationsNCT05944237
Recruiting
Phase 2

Comparing 3 vs 6 Cycles of Platinum-based Chemotherapy Prior to Maintenance Avelumab in Advanced Urothelial Cancer

Urinary Bladder Neoplasms
Queen Mary University of London320 enrolled3 locationsNCT06892860
Recruiting
Phase 3

Multicenter Clinical Trial on the Effectiveness and Safety of Instillation of BCG and Alternative BCG Protocols for Intermediate and High-risk Non-muscle Invasive Bladder Cancer

Urinary Bladder NeoplasmsTreatment OutcomeImmunotherapy, Active+3 more
Fujian Medical University Union Hospital76 enrolled1 locationNCT06441110
Recruiting

Prognostic Performance of a Chemogram in Patients With Bladder Cancer.

Urinary Bladder Neoplasms
Lille Catholic University60 enrolled1 locationNCT06403202
Recruiting

Prospective Sample Collection for Cancer of Bladder

Urinary Bladder Neoplasms
Universitaire Ziekenhuizen KU Leuven300 enrolled1 locationNCT03973671